Cellworks is a California incorporated life sciences lab less company with R & D footprint in Bangalore. The company focus is the design of molecularly-targeted therapies for complex diseases having multiple phenotypes. The design approach and methodology is a paradigm shift from conventional discovery approaches. This novel and predictive technology enables the virtualization of experiments. It allows the emulation of in vitro and in vivo systems under different environment conditions. The quantitative predictive markers are human physiological aligned and have been correlated with cell line and human clinical data endpoints.

The Cellworks therapies are architected based on multiple perturbations of pathways in the right proportion which are synergistic across efficacy phenotypes and diffusive at toxicity endpoints. Understanding of clinical outcomes early on avoids the cost and time cost due to attrition later in the process.

The Cellworks core disease focus areas include Oncology (solid state tumors) and Immunology (emphasis on Rheumatoid Arthritis). Cellworks has also incubated a "Bugworks" technology which emulates the micro-organisms, E. Coli and M. Tuberculosis. This technology is targeted at the Green chemistry and Bio-remediation area where it is being used to engineer designer strains capable of participating in whole cell catalysis.